Literature DB >> 12826744

The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach.

E Hogervorst1, S Bandelow, M Combrinck, S R Irani, S Irani, A D Smith.   

Abstract

Data from 204 participants from the Oxford Project to Investigate Memory and Ageing, who were diagnosed post-mortem using the histopathological criteria of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD), were used to assess the validity of the clinical criteria for Alzheimer's disease (AD) of the 'National Institute of Neurological and Communicative Disorders and Stroke/the Alzheimer's Disease and Related Disorders Association' (NINCDS/ADRDA). Cases who had been diagnosed as NINCDS/ADRDA 'probable AD' in life were usually confirmed at autopsy, but half of the NINCDS/ADRDA 'negative' cases were not (low specificity). It was hypothesized that the overall clinical impression may have taken precedence over the use of the actual criteria. We therefore investigated the validity and reliability of the clinical criteria using a computerized 'dementia diagnosis system' for each of 6 sets of criteria [Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), NINCDS/ADRDA and three sets of criteria specifically for vascular dementia (VaD): NINCDS-AIREN, State of California Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC), and Vascular Cognitive Impairment (VCI)] to classify a subset (n = 96) of the cases confirmed post-mortem. The use of the computerized system significantly (p = 0.01) increased the specificity (81%, similar to sensitivity) of the NINCDS/ADRDA diagnoses, which were shown to have 'moderate' inter-rater reliability. The DSM-IV criteria had good validity for AD when compared with post-mortem confirmation and showed 'substantial' inter-rater reliability. The ADDTC and VCI criteria for VaD had good specificity (88%) and sensitivity (75%), but only for one rater. The DSM-IV and NINCDS-AIREN criteria for VaD showed poor validity and inter-rater reliability. We conclude that the forced use of decision trees through a computerized system enhances the accuracy of the clinical diagnoses of dementia. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12826744     DOI: 10.1159/000071006

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  19 in total

Review 1.  Evolution of the diagnostic criteria for degenerative and cognitive disorders.

Authors:  Oscar L Lopez; Eric McDade; Mario Riverol; James T Becker
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

2.  Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow.

Authors:  Bich-Ngoc-Thanh Tang; Satoshi Minoshima; Jean George; Annie Robert; Christian Swine; Patrice Laloux; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-01       Impact factor: 9.236

3.  Diagnosis, risk factors, and treatment of vascular dementia.

Authors:  Oscar L Lopez; Lewis H Kuller; James T Becker
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

4.  Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Authors:  Barbara J Snider; Anne M Fagan; Catherine Roe; Aarti R Shah; Elizabeth A Grant; Chengjie Xiong; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2009-05

5.  Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013.

Authors:  Richard A Goodman; Kimberly A Lochner; Madhav Thambisetty; Thomas S Wingo; Samuel F Posner; Shari M Ling
Journal:  Alzheimers Dement       Date:  2016-05-10       Impact factor: 21.566

6.  Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment-Part 1.

Authors:  David R Weir; Robert B Wallace; Kenneth M Langa; Brenda L Plassman; Robert S Wilson; David A Bennett; Ranjan Duara; David Loewenstein; Mary Ganguli; Mary Sano
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

7.  An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin.

Authors:  Tapan K Khan; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-18       Impact factor: 11.205

8.  Novel domain expansion methods to improve the computational efficiency of the Chemical Master Equation solution for large biological networks.

Authors:  Rahul Kosarwal; Don Kulasiri; Sandhya Samarasinghe
Journal:  BMC Bioinformatics       Date:  2020-11-11       Impact factor: 3.169

9.  Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies.

Authors:  Ranjan Duara; David A Loewenstein; Maria Greig; Amarilis Acevedo; Elizabeth Potter; Jason Appel; Ashok Raj; John Schinka; Elizabeth Schofield; Warren Barker; Yougui Wu; Huntington Potter
Journal:  Am J Geriatr Psychiatry       Date:  2010-04       Impact factor: 4.105

10.  Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity.

Authors:  Peter T Nelson; Gregory A Jicha; Frederick A Schmitt; Huaichen Liu; Daron G Davis; Marta S Mendiondo; Erin L Abner; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.